BioGene Scores NICE Approval for Rare Lymphoma Drug Brukinsa

The UK’s National Institute for Health and Care Excellence (NICE) has approved BioGene’s drug Brukinsa for patients with Waldenstrom macroglobulinemia (WM), a rare form of B-cell lymphoma. The drug, approved for the same purpose last year in the US, will meet a previously unmet need due to issues with the current standard of care.

According to Kevin Dunleavy, “NICE called Brukinsa a “step change” in management of the disease, giving patients a chance to live longer and providing a better quality of life compared to standard of care. England’s price and cost watchdog also noted that Brukinsa is cost efficient at a range of 20,000 pounds sterling to 30,000 pounds ($22,808 to $34,212) per quality-adjusted life year.”

To read more, click here.

(Source: Fierce Pharma, September 10^th, 2022)